V114 15价肺炎球菌结合疫苗在≥50岁健康成人中的批间一致性、安全性、耐受性与免疫原性:一项随机3期试验(PNEU-TRUE)
本3期研究将≥50岁健康成人按3:3:3:1随机分配接种三批V114或PCV13,评估批间一致性、安全性与免疫原性。三批V114的所有15个疫苗血清型均达到预设等效标准,V114合并批次与PCV13组安全性相当,V114对22F和33F的免疫应答更高。
要点
- 三批V114在15个疫苗血清型上均达到批间等效标准,OPA GMT比值95%CI均在0.5-2.0内。
- V114组与PCV13组不良反应发生率相当,但注射部位疼痛在V114组更常报告。
- V114对13个共有血清型的免疫应答与PCV13相当,对独有血清型22F和33F的应答更高。
核心结论
- V114具有良好的耐受性,其安全性特征和免疫应答在制造批次间保持一致。
研究设计与样本
- 随机、3期、多中心(原文未明确中心数)试验(V114-020),健康成人≥50岁,按3:3:3:1随机接种单剂三批V114之一或PCV13,按年龄(50-64、65-74、≥75岁)分层。
- 纳入2340名参与者,2282名(97.5%)完成研究。
主要发现
- V114批次1、2、3中发生≥1次不良事件的参与者比例分别为81.0%、77.4%、78.0%。
- V114合并批次与PCV13组相比,不良事件、征集性不良事件和严重不良事件发生率相当,但注射部位疼痛在V114组更常报告。
- 接种后30天,三批V114的OPA GMTs和IgG GMCs相当,所有15个疫苗血清型均达到预设等效标准(所有两两比较的血清型特异性OPA GMT比值95%CI上下限均在0.5-2.0等效范围内)。
- V114合并批次与PCV13组在13个共有血清型上的OPA GMTs和IgG GMCs相当,V114组对独有血清型22F和33F的应答更高。
关键数值与推荐
- 批间等效标准:所有两两比较的血清型特异性OPA GMT比值95%CI均落在0.5-2.0范围内。
- 安全性评估:接种后14天内评估非严重不良事件,至第6个月评估严重不良事件。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Older adults are at risk of pneumococcal disease and associated morbidity and mortality. This phase 3 study (V114-020) assessed lot-to-lot consistency across safety and immunogenicity outcomes for V114, a 15-valent pneumococcal conjugate vaccine (PCV), in healthy adults aged ≥ 50 years. METHODS: Adults were randomized in a 3:3:3:1 ratio to receive a single dose of one of three lots of V114 or 13-valent PCV (PCV13), stratified by age (50-64 years, 65-74 years, and ≥ 75 years). Serotype-specific opsonophagocytic activity (OPA) and immunoglobulin G (IgG) antibodies were evaluated at baseline (Day 1) and 30 days post-vaccination. Non-serious and serious adverse events (AEs) were evaluated post-vaccination through 14 days and Month 6, respectively. RESULTS: Of 2340 participants enrolled, 2282 (97.5%) completed the study. Proportions of participants experiencing ≥ 1 AE were 81.0%, 77.4%, and 78.0% for V114 lots 1, 2, and 3, respectively. Comparison of V114 combined lots with PCV13 showed that proportions of participants experiencing AEs, solicited AEs, and serious AEs were comparable for both vaccines, with the exception of injection-site pain (more frequently reported with V114). OPA geometric mean titers (GMTs) and IgG geometric mean concentrations (GMCs) at 30 days post-vaccination were comparable across V114 lots, and all lots met predefined equivalence criteria for all 15 vaccine serotypes (lower and upper limits of the 95% confidence intervals of serotype-specific OPA GMT ratios for all possible pairwise comparisons across the three lots were within the equivalence margin of 0.5-2.0). Serotype-specific OPA GMTs and IgG GMCs were comparable in the V114 combined lots and PCV13 groups for the 13 shared serotypes and higher in the V114 group for serotypes unique to V114 (22F and 33F). CONCLUSIONS: V114 is well tolerated with a consistent safety profile and immune response across manufacturing lots. CLINICAL TRIALS REGISTRATION: NCT03950856 (www.clinicaltrials.gov); 2018-004266-33 (EudraCT).
引用
- Simon JK, Staerke NB, Hemming-Harlo M, et al. Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE). Vaccine. 2022. PMID: 35039194. doi:10.1016/j.vaccine.2021.12.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。